VENUS MEDTECH-B(02500): Cardiovalve Ltd. and MTH IP, L.P. filed a patent infringement lawsuit against Edwards for US Patent No. 385.
Qi Ming Medical - B (02500) announced on June 9, 2025 that the United States Federal Circuit Court of Appeals has ruled to confirm the validity of certain patent claims of the US Patent No. 10,702,385 (Implantable Heart Valve) owned by Cardiovalve Ltd. (referred to as the 385th Patent), while Edwards Lifesciences Corp. and Edwards Lifesciences LLC (referred to as "Edwards") had raised objections to the patent during a dual review process in June 2021.
VENUS MEDTECH-B (02500) announces that on June 9, 2025, the United States Federal Circuit Court of Appeals ruled to confirm the validity of certain claims of US Patent No. 10,702,385 (Heart Valve Implant) held by Cardiovalve Ltd. (the '385 Patent), while Edwards Lifesciences Corp. and Edwards Lifesciences LLC (collectively "Edwards") had challenged the patent in a review process in June 2021. On January 14, 2026, Cardiovalve Ltd. and MTH IP, L.P. filed a patent infringement lawsuit against Edwards in the District Court of Delaware relating to the '385 Patent, alleging that Edwards' core product PASCAL Precision valve repair system infringes the '385 Patent owned by Cardiovalve Ltd.
As the lawsuit is still in its preliminary stages, further details (including potential claims amounts) will depend on the outcome of the litigation. The company will make further announcements in accordance with the listing rules of the Hong Kong Stock Exchange at the appropriate time regarding any material developments in the lawsuit.
Related Articles

HK Stock Market Move | SUNSHINE PHARMA (06887) rose over 6% in the afternoon, with Class 1 new drug Ologliptin approved for listing. Recently launched an AI intelligent research and development platform.

Goldman Sachs raises year-end gold price forecast to $5400

HK Stock Market Move | XPENG-W (09868) fell more than 3% and announced the launch of a full range 7-year low-interest installment purchase plan.
HK Stock Market Move | SUNSHINE PHARMA (06887) rose over 6% in the afternoon, with Class 1 new drug Ologliptin approved for listing. Recently launched an AI intelligent research and development platform.

Goldman Sachs raises year-end gold price forecast to $5400

HK Stock Market Move | XPENG-W (09868) fell more than 3% and announced the launch of a full range 7-year low-interest installment purchase plan.

RECOMMEND

Moving Toward “7*24 Hour” Trading! NYSE Seeks Approval For “All‑Weather Blockchain Trading Platform”
21/01/2026

China Internet 2026: Under Pressure From ByteDance, Major Players Launch Full‑Scale Contest For AI Entry Points
21/01/2026

Hong Kong Equity Refinancing Opens Strong In 2026, Raising Over HKD 27 Billion
21/01/2026


